Inovio Pharmaceuticals Inc (NASDAQ:INO) – Research analysts at Piper Jaffray Companies dropped their FY2019 earnings estimates for shares of Inovio Pharmaceuticals in a research report issued on Tuesday, November 12th, according to Zacks Investment Research. Piper Jaffray Companies analyst C. Raymond now anticipates that the biopharmaceutical company will post earnings of ($1.09) per share for the year, down from their prior estimate of ($0.87). Piper Jaffray Companies also issued estimates for Inovio Pharmaceuticals’ Q4 2019 earnings at ($0.24) EPS, Q3 2020 earnings at ($0.01) EPS, Q4 2020 earnings at ($0.23) EPS, FY2020 earnings at ($0.72) EPS, Q1 2021 earnings at ($0.22) EPS, Q2 2021 earnings at ($0.23) EPS, Q3 2021 earnings at ($0.23) EPS, FY2021 earnings at ($0.94) EPS, FY2022 earnings at ($0.48) EPS and FY2023 earnings at ($0.01) EPS.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The company had revenue of $0.87 million during the quarter, compared to the consensus estimate of $2.72 million. Inovio Pharmaceuticals had a negative return on equity of 179.91% and a negative net margin of 1,809.64%. During the same period last year, the firm earned ($0.27) earnings per share.
Several other analysts also recently weighed in on the company. Maxim Group restated a “buy” rating on shares of Inovio Pharmaceuticals in a research note on Thursday, November 14th. Citigroup restated a “buy” rating and set a $4.00 target price (down from $7.00) on shares of Inovio Pharmaceuticals in a research note on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $6.69.
Shares of Inovio Pharmaceuticals stock traded down $0.07 during trading hours on Friday, hitting $2.52. 607,879 shares of the company’s stock traded hands, compared to its average volume of 947,097. The stock has a 50 day simple moving average of $2.36 and a 200-day simple moving average of $2.55. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 2.52. The company has a market cap of $259.03 million, a PE ratio of -2.40 and a beta of 2.05. Inovio Pharmaceuticals has a twelve month low of $1.91 and a twelve month high of $5.47.
A number of hedge funds have recently added to or reduced their stakes in the business. State Street Corp increased its stake in Inovio Pharmaceuticals by 0.4% during the third quarter. State Street Corp now owns 1,744,448 shares of the biopharmaceutical company’s stock valued at $3,576,000 after purchasing an additional 6,998 shares during the last quarter. SG Americas Securities LLC bought a new stake in Inovio Pharmaceuticals during the third quarter valued at $141,000. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Inovio Pharmaceuticals by 5.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,156,350 shares of the biopharmaceutical company’s stock valued at $10,571,000 after purchasing an additional 272,250 shares during the last quarter. Nikko Asset Management Americas Inc. increased its stake in Inovio Pharmaceuticals by 5.6% during the third quarter. Nikko Asset Management Americas Inc. now owns 5,156,350 shares of the biopharmaceutical company’s stock valued at $10,571,000 after purchasing an additional 272,250 shares during the last quarter. Finally, Wedbush Securities Inc. bought a new stake in Inovio Pharmaceuticals during the third quarter valued at $34,000. Hedge funds and other institutional investors own 46.38% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.